136 related articles for article (PubMed ID: 36331521)
1. Mitigating the BFL1-mediated antiapoptotic pathway in diffuse large B cell lymphoma by inhibiting HDACs.
Park E; Lee C; Park J; Liu J; Hong J; Shin DY; Byun JM; Yun H; Koh Y; Yoon SS
Leuk Lymphoma; 2023 Jan; 64(1):205-216. PubMed ID: 36331521
[TBL] [Abstract][Full Text] [Related]
2. NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death.
Liu Y; Mondello P; Erazo T; Tannan NB; Asgari Z; de Stanchina E; Nanjangud G; Seshan VE; Wang S; Wendel HG; Younes A
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):12034-12039. PubMed ID: 30404918
[TBL] [Abstract][Full Text] [Related]
3. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.
Luo C; Yu T; Young KH; Yu L
J Zhejiang Univ Sci B; 2022 Aug; 23(8):666-681. PubMed ID: 35953760
[TBL] [Abstract][Full Text] [Related]
4. Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway.
Zhang H; Chi F; Qin K; Mu X; Wang L; Yang B; Wang Y; Bai M; Li Z; Su L; Yu B
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33649847
[TBL] [Abstract][Full Text] [Related]
5. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
Li J; Qian C; Zhou Q; Li J; Li K; Yi P
Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223
[TBL] [Abstract][Full Text] [Related]
6. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
7. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
Thompson RC; Vardinogiannis I; Gilmore TD
PLoS One; 2013; 8(5):e62822. PubMed ID: 23667527
[TBL] [Abstract][Full Text] [Related]
8. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy.
Gupta M; Han JJ; Stenson M; Wellik L; Witzig TE
Leukemia; 2012 Jun; 26(6):1356-64. PubMed ID: 22116549
[TBL] [Abstract][Full Text] [Related]
9. Targeting HDACs for diffuse large B-cell lymphoma therapy.
Wu C; Song Q; Gao S; Wu S
Sci Rep; 2024 Jan; 14(1):289. PubMed ID: 38168914
[TBL] [Abstract][Full Text] [Related]
10. Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance.
Lee SH; Yoo C; Im S; Jung JH; Choi HJ; Yoo J
Int J Med Sci; 2014; 11(10):994-1000. PubMed ID: 25076845
[TBL] [Abstract][Full Text] [Related]
11. [In vitro pharmacodynamic studies of novel class Ⅰ and Ⅱb selective histone deacetylase inhibitor purinostat mesylate in the treatment of diffuse large B-cell lymphoma and its mechanism].
Wang J; Zhao AL; Li H; Yang LY; Chen LJ; Niu T
Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):753-759. PubMed ID: 36709169
[No Abstract] [Full Text] [Related]
12. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
[TBL] [Abstract][Full Text] [Related]
13. Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
Zhang K; Huang L; Lai F; Lin S; Tian H; Wu D; Chen X; Xu H
Bioorg Med Chem Lett; 2022 Sep; 71():128825. PubMed ID: 35644299
[TBL] [Abstract][Full Text] [Related]
14. Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism.
Li X; He Z; Cheng B; Fang Q; Ma D; Lu T; Wei D; Kuang X; Tang S; Xiong J; Wang J
Cancer Biol Ther; 2018; 19(9):825-834. PubMed ID: 29969367
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.
Cycon KA; Mulvaney K; Rimsza LM; Persky D; Murphy SP
Immunology; 2013 Oct; 140(2):259-72. PubMed ID: 23789844
[TBL] [Abstract][Full Text] [Related]
16. Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma.
Kim SJ; Kim UJ; Yoo HY; Choi YJ; Kang KW
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575557
[TBL] [Abstract][Full Text] [Related]
17. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20.
Guan XW; Wang HQ; Ban WW; Chang Z; Chen HZ; Jia L; Liu FT
Cell Death Dis; 2020 Jan; 11(1):20. PubMed ID: 31907371
[TBL] [Abstract][Full Text] [Related]
18. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
19. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response.
Mensah AA; Kwee I; Gaudio E; Rinaldi A; Ponzoni M; Cascione L; Fossati G; Stathis A; Zucca E; Caprini G; Bertoni F
Oncotarget; 2015 Mar; 6(7):5059-71. PubMed ID: 25671298
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Batlevi CL; Crump M; Andreadis C; Rizzieri D; Assouline SE; Fox S; van der Jagt RHC; Copeland A; Potvin D; Chao R; Younes A
Br J Haematol; 2017 Aug; 178(3):434-441. PubMed ID: 28440559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
